Yesterday, I published a list of several stocks you want to own this week, certainly on the list was one of the companies we've been following most closely, Neostem, Inc. (AMEX: NBS). If you still haven't picked up any shares, you may want to because things are about to get a lot more interesting for this undervalued "stem cell play with a twist."
Recently, the company announced the recent approval from the State Food and Drug Administration (SFDA) in China to manufacture the sterile active pharmaceutical ingredient (API) of the anti-infective cloxacillin sodium. This is the second of seven drugs in Erye's pipeline to be approved since the October 31st, 2009 acquisition of the 51% interest in Erye. Both drugs are on the China’s National Medical Reimbursement Insurance List and thus is eligible for reimbursement by the government's healthcare programs. Commercially launch for both drugs is planned for this summer.
The acquisition of Eyre has completely re-shaped the company and investors have barely noticed. After having owned only 2 months of Suzhou Erye’, the company reported over 11m dollars in revenues for 2009. Year end financials support Suzhou Erye’s growth and Revenues for 2010 should be over 80 million dollars and potentially higher with acceleration of the relocation to the new plant which should double their capacity.
Additionally, the company expects to see a number of new license deals from the U.S. to sell in China. This is a significant development and it will mean big profits without big investments. In additon, the fact that a trusted American company can guide other American companies through the "license to China" process in order to get their products into the hands of consumers there will be a major step which can be repeated time and again by Neostem. As I've said before, when NBS acquired the Chinese pharmaceutical operation, they- in essence- created their own printing press for new money.
Neostem announced moving to Deloitte for their 2010 audit. Why? Because the markets more readily trust that the numbers are real. Insiders
increased buying of shares through the purchase of warrants at a price much higher than where the stock is trading now. This should tell investors just how undervalued those close to the company believe shares are. Additionally, RimAsia the largest NBS shareholder exercised its NeoStem warrant to purchase 1,000,000 shares, issued in a September 2008 private placement (“2008 Warrant”), at a price of $1.75 per share for gross proceeds to the Company of $1,750,000. RimAsia is currently subject to a lock-up agreement. The transaction was approved by the independent audit committee when the Company’s common stock was trading at $1.42.
Let’s not forget the potential impact of the stem cell side of the business in an industry projected to generate 88 Billion dollars annually world wide by 2014. The launch of therapeutic programs with innovative stem cell technologies cosmetic and anti-aging applications in People’s Republic of China (PRC) and Taiwan appear to be on track . Wendeng Orthopedic Hospital commenced operations in the first quarter of 2010 with revenues expected during the second quarter of 2010. Enhance BioMedical Holdings Limited (EBH) is expected to begin in the second quarter of 2010 adult stem cell collection and storage activities to enable it to launch the application of cosmetic and anti-aging therapies in Taiwan during the summer of 2010. EBH is also astrategic investor buying 5 million dollars worth of equity in April 2009.
As therapies emerge, NeoStem stem cell collection and storage business in its U.S. will undoubtedly grow. In the first quarter, the Company expanded into the southwestern region of the US with the addition of the physician group at Westlake Orthopaedics Spine & Sports in Austin, TX launching In the second quarte. NeoStem is preparing to launch an adult stem cell collection center at its new R&D facility in Cambridge, MA this quarter. These collection centers will not only provide expected new sources of revenue but also further strengthen the Company’s leadership in adult stem cell collection and storage.
Letters of Intents (LOI) have been executed between the Company’s Chinese consultant and Shandong Life Science and Technology Research Institute and Peking University Diabetes Center, Beijing Institute of Geriatrics, Ministry of Health and Shandong University to expedite the clinical trials of their promising adult stem cell VSEL ™ technology. These are the very small adult stem cells with properties similar to those of embryonic stem cells. These cells have the potential to achieve the positive benefits associated with embryonic stem cells without the ethical or moral dilemmas or certain of the potential negative effects associated with embryonic stem cells. As the world-wide license holder to VSEL ™ technology, NeoStem remains in discussions with a number of researchers to generate data relating to other clinical applications of very small embryonic-like stem cells, including neural, cardiac, and ophthalmic disease, to expand our research efforts and maximize the value of this technology.
Disclosure: Long NBS
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites